Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineAdjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Adjuvant olaparib (Lynparza) was linked with significantly longer life free of invasive or distant illness compared to placebo among patients with high-risk, HER2-negative early breast cancer and germline BRCA1 or BRCA2 pathogenic or possibly pathogenic mutations. Global patient-reported quality of life was not significantly impacted by olaparib.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form